Impel NeuroPharma (NASDAQ:IMPL) Releases Earnings Results, Beats Estimates By $0.39 EPS

Impel NeuroPharma (NASDAQ:IMPL) posted its quarterly earnings results on Sunday. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.39, Yahoo Finance reports.

Shares of IMPL stock traded down $0.35 during trading hours on Tuesday, reaching $10.23. The company’s stock had a trading volume of 50,355 shares, compared to its average volume of 83,869. Impel NeuroPharma has a one year low of $9.08 and a one year high of $15.89.

In other Impel NeuroPharma news, major shareholder Vivo Capital Viii, Llc acquired 575,000 shares of the business’s stock in a transaction dated Tuesday, April 27th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $8,625,000.00. Following the transaction, the insider now owns 98,927 shares in the company, valued at $1,483,905. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Several equities analysts recently issued reports on IMPL shares. Guggenheim started coverage on Impel NeuroPharma in a research report on Tuesday, May 18th. They set a “buy” rating and a $32.00 price target on the stock. Wedbush started coverage on Impel NeuroPharma in a research report on Tuesday, May 18th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Cowen started coverage on Impel NeuroPharma in a research report on Tuesday, May 18th. They set an “outperform” rating and a $35.00 price target on the stock.

About Impel NeuroPharma

Impel NeuroPharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.

Featured Article: What is basic economics?

Receive News & Ratings for Impel NeuroPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel NeuroPharma and related companies with MarketBeat.com's FREE daily email newsletter.